Can I Take Folate with Vyleesi (Bremelanotide)?

What Is Bremelanotide and Why Does the Folate Question Arise?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019 under NDA 210557 for hypoactive sexual desire disorder (HSDD) in premenopausal women. [1] It is dosed as a single 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than eight times per month. Women taking Vyleesi often take folate or methylfolate for general reproductive health, MTHFR support, or because they are planning a future pregnancy. The natural question is whether those supplements interfere with how bremelanotide works.

How Bremelanotide Works

Bremelanotide binds melanocortin receptors MC1R, MC3R, MC4R, and MC5R in the central nervous system. [2] MC4R activation in the hypothalamus is thought to mediate its pro-sexual effect. The drug does not act through serotonin, dopamine reuptake inhibition, or hormonal pathways in a way that would overlap with folate biochemistry. [3]

Why Folate Comes Up for This Population

HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States. [4] Many of these women are of reproductive age, and current CDC guidance recommends 400 mcg of folic acid daily for all women capable of becoming pregnant to prevent neural tube defects. [5] Separately, the MTHFR C677T variant is carried by roughly 10 to 15 percent of people of European ancestry in homozygous form, impairing conversion of folic acid to active 5-methyltetrahydrofolate (5-MTHF). [6] These two facts together mean folate supplementation is common in the exact population prescribed Vyleesi.

Does Folate Interact with Vyleesi Pharmacokinetically?

No published pharmacokinetic study documents an interaction between folate and bremelanotide. The metabolic pathways are entirely separate, and the FDA prescribing information for Vyleesi does not list folate among interacting substances. [1]

Bremelanotide Metabolism

After subcutaneous injection, bremelanotide reaches peak plasma concentration (Tmax) in approximately 1 hour. It is metabolized primarily via peptide hydrolysis, not through cytochrome P450 enzymes. [1] The FDA label states no clinically significant CYP-mediated drug interactions are expected. Folate is absorbed via intestinal folate transporters (SLC19A1, PCFT), distributed to tissues, and converted through one-carbon metabolism reactions in the cytosol and mitochondria. [7] These two pathways do not converge at any enzyme, transporter, or receptor relevant to either compound's pharmacology.

Protein Binding and Renal Clearance

Bremelanotide is approximately 21 percent protein-bound in vitro and is cleared renally, with a terminal half-life near 2.7 hours. [1] Folate circulates partly bound to folate-binding proteins. Neither compound meaningfully displaces the other from shared binding sites. Women with severe renal impairment (eGFR <30 mL/min/1.73 m²) should exercise caution with bremelanotide due to increased exposure; those same women may also need monitoring of folate status given reduced renal handling of water-soluble vitamins, but this is a parallel concern, not an interaction. [8]

Does Folate Interact with Vyleesi Pharmacodynamically?

A pharmacodynamic interaction would require folate to amplify or blunt bremelanotide's effect on sexual desire, blood pressure, or nausea. No evidence supports that.

Blood Pressure Effects

The most clinically significant adverse effect of bremelanotide is a transient increase in blood pressure. In the pooled Phase 3 trials (RECONNECT studies, N=1,267), mean systolic BP rose approximately 1.9 mmHg and diastolic BP rose approximately 1.6 mmHg within 12 hours of dosing. [9] High-dose folic acid (5 mg/day) has been studied for its effects on endothelial function and nitric oxide bioavailability, with some trials showing modest antihypertensive effects. [10] This is not a harmful combination; if anything, folate's mild vasodilatory properties would not be expected to worsen bremelanotide-related BP rises, though no head-to-head study has confirmed this.

Nausea Pathway

Nausea occurred in 40 percent of bremelanotide-treated women in RECONNECT versus 1 percent with placebo. [9] This is mediated through central melanocortin pathways. Folate has no known antiemetic or pro-emetic mechanism at the central melanocortin level. [11] Women may choose to take their folate supplement with food earlier in the day rather than immediately before a Vyleesi injection simply to avoid compounding any GI discomfort, though no clinical data mandate this.

Sexual Desire Endpoints

The RECONNECT trials used the Female Sexual Function Index (FSFI) desire domain and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) as co-primary endpoints. [9] Folate status has not been evaluated as a modifier of bremelanotide's effect on either endpoint. Folate deficiency has been loosely associated with fatigue and mood changes that could theoretically affect sexual desire independently, but no trial has tested folate repletion as an adjunct to bremelanotide therapy. [12]

MTHFR, Methylation, and Vyleesi: What You Need to Know

MTHFR variants affect folate metabolism, not melanocortin signaling. This is a separate clinical consideration from any Vyleesi interaction, but it is relevant for women choosing which form of folate to take.

Folic Acid vs. Methylfolate

Women with homozygous MTHFR C677T have reduced MTHFR enzyme activity by approximately 70 percent, impairing conversion of dietary folic acid to the bioavailable 5-MTHF. [6] For these women, supplementing with L-methylfolate (5-MTHF) at doses of 400 to 1,000 mcg per day bypasses the enzymatic block. [13] This has no bearing on bremelanotide pharmacology, but it matters for achieving adequate folate status.

Anticonvulsant Co-Use

Some women taking antiepileptic drugs (AEDs) such as valproate or carbamazepine require high-dose folic acid (1 to 5 mg/day) because AEDs deplete folate through enzyme induction or direct antagonism. [14] Carbamazepine is also a potent CYP3A4 inducer. Bremelanotide is not a CYP3A4 substrate to a clinically meaningful degree, so AED co-use primarily raises a folate-deficiency concern rather than a three-way drug-supplement interaction. Women on AEDs should discuss both their AED and bremelanotide with their neurologist and prescribing clinician.

Homocysteine and Vascular Health

Elevated homocysteine from folate deficiency is associated with endothelial dysfunction and elevated cardiovascular risk. [15] Because bremelanotide transiently raises blood pressure, women with pre-existing hypertension or hyperhomocysteinemia may benefit from optimizing their folate, B12, and B6 status before initiating Vyleesi. This is a background health consideration, not a direct interaction.

Recommended Folate Dosing Alongside Vyleesi

Standard folate supplementation is compatible with bremelanotide at every approved dose level.

The following framework reflects current CDC, ACOG, and prescribing-label guidance synthesized for women combining folate with Vyleesi:

| Patient Profile | Recommended Folate Form | Daily Dose | Timing vs. Vyleesi | |---|---|---|---| | General premenopausal women | Folic acid | 400 to 800 mcg | Any time; no separation needed | | MTHFR C677T homozygous | L-methylfolate (5-MTHF) | 400 to 1,000 mcg | Any time; no separation needed | | On AEDs (valproate, carbamazepine) | Folic acid | 1 to 5 mg (prescriber-directed) | Any time | | Periconceptional planning | Folic acid or methylfolate | 400 to 800 mcg | Any time; note Vyleesi is contraindicated in confirmed pregnancy | | Folate deficiency documented | Folic acid | 1 mg/day until repleted | Any time |

ACOG recommends that all women of reproductive age consume 400 mcg of folic acid daily, stating: "Women who have previously had a pregnancy affected by a neural tube defect should take 4 mg of folic acid per day beginning one to three months before conception." [16] This recommendation applies regardless of concurrent medications, and bremelanotide does not alter it.

What the FDA Label Says About Interactions

The Vyleesi full prescribing information (revised 2019) lists the following relevant interactions: naltrexone (reduced naltrexone Cmax by approximately 35 percent when co-administered), and potential transient decreases in the rate of absorption of orally co-administered drugs due to bremelanotide's ability to slow gastric emptying. [1] Folate is not mentioned because no interaction exists in the approved labeling.

Oral Absorption Slowing: Does It Affect Folate Tablets?

Bremelanotide may transiently slow gastric emptying, which could in theory delay the absorption of oral medications taken around the same time. [1] Folate is absorbed primarily in the proximal jejunum via the proton-coupled folate transporter (PCFT/SLC46A1). [7] A delay in gastric emptying would push intestinal absorption slightly later, not reduce total absorption. No pharmacokinetic study has shown reduced bioavailability of folate when gastric emptying is modestly slowed. To be conservative, taking your folate supplement two to three hours before the Vyleesi injection is a reasonable precaution, though not mandatory.

Drugs That Do Interact with Bremelanotide

For completeness, the FDA label cautions about naltrexone co-administration, and the general class warning about oral drugs with narrow therapeutic windows (e.g., certain antibiotics, hormonal contraceptives) applies due to the gastric-emptying effect. [1] Women taking levothyroxine, narrow-therapeutic-index AEDs, or other time-sensitive oral drugs should discuss the injection timing with their prescriber, separate from any folate question.

Monitoring Recommendations

Routine lab monitoring is not required solely because a woman is taking folate with bremelanotide. Certain clinical situations do warrant monitoring.

Blood Pressure

The FDA label recommends checking blood pressure before starting Vyleesi and advises against use in women with uncontrolled hypertension or cardiovascular disease. [1] Measuring BP at baseline and periodically during the first few months of use is standard practice regardless of supplement use. [17]

Folate Status

Checking serum folate or red blood cell folate is warranted when there is clinical suspicion of deficiency: macrocytic anemia, fatigue, or dietary restriction. [18] Women with MTHFR variants may benefit from measuring plasma homocysteine as a functional marker of folate adequacy. [6] These assessments are independent of bremelanotide use.

Renal Function

Women with chronic kidney disease should have their eGFR assessed before starting bremelanotide, as the FDA label contraindicates use when eGFR <30 mL/min/1.73 m². [1] Folate is water-soluble and generally safe across renal function ranges at standard doses, though high-dose supplementation above 5 mg/day in advanced CKD may warrant nephrology input. [8]

When to Contact Your Prescriber

Contact your clinician promptly if you notice any of the following after starting Vyleesi, regardless of your folate use:

• Blood pressure readings above 140/90 mmHg on home monitoring within 12 hours of an injection.
• Flushing or skin hyperpigmentation that persists beyond 72 hours (focal melanocortin activation can cause transient hyperpigmentation). [1]
• Severe nausea that does not resolve within 12 hours.
• A missed menstrual period, since Vyleesi is contraindicated in pregnancy and adequate folate becomes especially important periconceptionally. [19]

Special Populations

Women Planning Pregnancy

Bremelanotide carries FDA Pregnancy Category X labeling. Animal studies showed embryo-fetal toxicity at exposures below the human clinical dose. [1] Women who are trying to conceive should not use Vyleesi during conception attempts. The periconceptional period is precisely when folate supplementation is most critical: CDC and ACOG guidance supports starting 400 to 800 mcg folic acid at least one month before conception. [5, 16] These two recommendations (stop Vyleesi before conception attempts, continue folate) are complementary rather than contradictory.

Women with a History of Neural Tube Defect Pregnancies

ACOG specifies 4 mg of folic acid per day for women with a prior NTD-affected pregnancy, beginning one to three months before conception. [16] If such a woman is also being treated for HSDD, the high-dose folic acid regimen should be maintained. No dose adjustment for bremelanotide is needed on this basis.

Postmenopausal Transition

Vyleesi is approved only for premenopausal women. Folate needs do not change dramatically at menopause, though the periconceptional argument for supplementation no longer applies. Women approaching perimenopause taking Vyleesi should clarify their ongoing indication with their prescriber as ovarian function changes.

Clinical Summary: What to Tell Your Prescriber

Give your prescriber a complete supplement list at every visit. For folate specifically, share:

1. The form you are taking (folic acid vs. L-methylfolate).
2. The daily dose in micrograms or milligrams.
3. Whether you have a known MTHFR variant.
4. Any other medications that affect folate metabolism (AEDs, methotrexate, sulfasalazine, proton-pump inhibitors at high dose). [14]

The American College of Obstetricians and Gynecologists states in Practice Bulletin No. 187: "Clinicians should counsel patients about the safety and efficacy of all medications used for sexual dysfunction, including potential interactions with other therapies." [20] Applying that standard to supplements means disclosing folate use even when, as here, no interaction is expected.